<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526926</url>
  </required_header>
  <id_info>
    <org_study_id>CPX351-402</org_study_id>
    <nct_id>NCT03526926</nct_id>
  </id_info>
  <brief_title>A Post-Marketing Observational Study of VYXEOS™</brief_title>
  <official_title>A Post-Marketing Observational Study of VYXEOS™ to Assess the Incidence of Infusion-Related Reactions in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to provide data on the incidence and severity of
      infusion-related reactions during and immediately following each infusion of VYXEOS during
      the first induction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infusion-Related Reactions on Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The investigator will assess each AE and indicate if it as an infusion-related reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infusion-Related Reactions Occurring until One Day after the Last Infusion</measure>
    <time_frame>1 day after the last infusion</time_frame>
    <description>The number and percentage of patients assessed by the investigator to have had any AEs assessed to be an infusion-related reaction occurring until 1 day after the last infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital Signs</measure>
    <time_frame>Up to 180 minutes after the start of infusion</time_frame>
    <description>Descriptive statistics for observed vital signs will be provided for each infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>1 day after the last infusion</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) are defined as any AE starting after the initiation of the first infusion of VYXEOS</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia With Myelodysplasia-Related Changes</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Vyxeos</arm_group_label>
    <description>A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.</description>
    <arm_group_label>Vyxeos</arm_group_label>
    <other_name>Vyxeos</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A minimum of 50 patients who have received at least one infusion of prescribed VYXEOS at a
        dose of 44 mg/m2 daunorubicin and 100 mg/m2 cytarabine are planned for this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The decision to prescribe VYXEOS must have been made prior to enrollment in this study
             and based upon approved US indications and dosing: 44mg/m2 daunorubicin and cytarabine
             100 mg/2 on Days 1, 3, and 5.

          2. Ability to understand and voluntarily give informed consent and understand the
             requirements of the registry.

          3. Age ≥ 18 years.

          4. Initiating VYXEOS therapy for the first time according to the current prescribing
             information.

          5. Initiating VYXEOS therapy for the first time according to standard institutional
             practice.

        Exclusion Criteria:

          1. Prior treatment with VYXEOS.

          2. Patients receiving any investigational agent other than VYXEOS (e.g., any drug or
             biologic agent or medical device that has not received approval in the US) or
             receiving VYXEOS for any indication not currently approved in the US.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>(215) 832-3750</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly-diagnosed t-AML or AML-MRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

